Acadia Pharmaceuticals (ACAD) EBIT (2010 - 2026)

Acadia Pharmaceuticals' EBIT history runs 17 years deep, the most recent figure standing at -$4.6 million for Q1 2026.

• On a quarterly basis, EBIT fell 123.93% year-over-year to -$4.6 million in Q1 2026; TTM through Mar 2026 was $80.9 million, a 65.55% decrease from a year earlier, with the FY2025 full-year figure at $104.8 million, down 54.59% from the prior year.
• EBIT eased to -$4.6 million in Q1 2026 per ACAD's latest filing, from $17.4 million in the prior quarter.
• Across five years, EBIT topped out at $153.5 million in Q4 2024 and bottomed at -$113.0 million in Q1 2022.
• The 5-year median for EBIT is $15.2 million (2024), against an average of $2.0 million.
• Across the five-year window, EBIT jumped 902.21% in 2024 and tumbled 123.93% in 2026, its largest moves.
• Year by year, EBIT stood at -$46.1 million in 2022, then surged by 175.86% to $34.9 million in 2023, then jumped by 339.28% to $153.5 million in 2024, then sank by 88.67% to $17.4 million in 2025, then plunged by 126.54% to -$4.6 million in 2026.
• Per Business Quant, the three latest ACAD EBIT figures stand at -$4.6 million (Q1 2026), $17.4 million (Q4 2025), and $35.8 million (Q3 2025).